Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,757,368
  • Shares Outstanding, K 2,035,753
  • Annual Sales, $ 48,300 M
  • Annual Income, $ -8,948 M
  • EBIT $ 12,215 M
  • EBITDA $ 21,815 M
  • 60-Month Beta 0.29
  • Price/Sales 2.15
  • Price/Cash Flow 8.66
  • Price/Book 5.58

Options Overview Details

View History
  • Implied Volatility 23.18% (-1.34%)
  • Historical Volatility 33.99%
  • IV Percentile 8%
  • IV Rank 9.64%
  • IV High 55.70% on 04/10/25
  • IV Low 19.71% on 12/26/24
  • Expected Move (DTE 7) 1.28 (2.44%)
  • Put/Call Vol Ratio 0.79
  • Today's Volume 18,233
  • Volume Avg (30-Day) 55,093
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 881,560
  • Open Int (30-Day) 891,634
  • Expected Range 50.90 to 53.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.65
  • Number of Estimates 9
  • High Estimate 1.71
  • Low Estimate 1.57
  • Prior Year 1.67
  • Growth Rate Est. (year over year) -1.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.26 +15.59%
on 11/20/25
52.51 -0.36%
on 12/05/25
+5.85 (+12.59%)
since 11/05/25
3-Month
42.52 +23.05%
on 10/29/25
52.51 -0.36%
on 12/05/25
+5.18 (+10.99%)
since 09/05/25
52-Week
42.52 +23.05%
on 10/29/25
63.33 -17.39%
on 03/11/25
-6.52 (-11.08%)
since 12/05/24

Most Recent Stories

More News
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile ...

BMY : 52.36 (+0.79%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 19.43 (-2.61%)
GTBP : 0.6000 (-4.73%)
ROIV : 20.99 (-0.90%)
CCCC : 2.65 (+2.32%)
BMY : 52.36 (+0.79%)
3 Stocks Under $50 We’re Skeptical Of

3 Stocks Under $50 We’re Skeptical Of

AMPL : 11.21 (+2.00%)
BHE : 46.93 (+0.28%)
BMY : 52.36 (+0.79%)
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Study Continuation Follows Review of Site Level Data and Recommendation of Data Monitoring Committee BMS Remains Blinded to Study Data

BMY : 52.36 (+0.79%)
Option Volatility and Earnings Report for December 1 - 5

Earnings season is starting to wind down but we still have some big names due to report including Salesforce, Crowdstrike, Marvell Technologies, Snowflake, Dollar Tree and Dollar General.

TWLO : 127.09 (+1.49%)
GOOG : 320.99 (+0.82%)
CRWD : 523.21 (+1.97%)
SNOW : 229.27 (-2.34%)
DLTR : 123.62 (+6.69%)
NEM : 90.66 (-0.07%)
RIVN : 18.15 (+0.50%)
VALE : 13.32 (-1.77%)
COIN : 268.84 (-1.90%)
CRM : 261.07 (+5.50%)
MRVL : 99.19 (+1.02%)
BMY : 52.36 (+0.79%)
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma First-in-class lymphoma CELMoDâ„¢ agent, golcadomide, delivers durable...

BMY : 52.36 (+0.79%)
Is Bristol-Myers Stock Underperforming the S&P 500?

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

$SPX : 6,876.19 (+0.28%)
AMGN : 332.32 (-2.30%)
BMY : 52.36 (+0.79%)
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will take...

BMY : 52.36 (+0.79%)
Is Amgen Stock Underperforming the Nasdaq?

Amgen has underperformed the Nasdaq over the past year, but analysts are still fairly bullish about the biopharma stock's growth potential.

$NASX : 23,566.34 (+0.26%)
AMGN : 332.32 (-2.30%)
BMY : 52.36 (+0.79%)
Is Gilead Sciences Stock Outperforming the Dow?

Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.

XLV : 153.76 (-0.09%)
$DOWI : 47,976.85 (+0.26%)
GILD : 120.85 (-1.44%)
BMY : 52.36 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 54.47
2nd Resistance Point 53.27
1st Resistance Point 52.61
Last Price 52.36
1st Support Level 50.76
2nd Support Level 49.56
3rd Support Level 48.90

See More

52-Week High 63.33
Fibonacci 61.8% 55.38
Fibonacci 50% 52.93
Last Price 52.36
Fibonacci 38.2% 50.47
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar